Prescribing overview
Carafate is human-labeled ulcer therapy. That label does not establish an animal indication or regimen.
Key prescribing checks
- Sucralfate can reduce absorption of several concurrent drugs. Plan administration timing with the prescriber using the full interaction information.
- Renal impairment merits special assessment because aluminum accumulation is a labeled concern. Constipation is also reported; reassess adverse effects rather than automatically continuing.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Veterinary patients: not established by reviewed label
Extra-label veterinary use; reviewed product is human-labeledVeterinarian-selected mucosal protection
Human indication is active duodenal ulcer; animal efficacy and eligibility need separate assessment.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Forms an ulcer-adherent local barrier against acid, pepsin and bile salts rather than acting as a systemic acid suppressant.
Absorption, distribution, metabolism and elimination
The human label describes minimal gastrointestinal absorption; no quantitative veterinary PK is verified here.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Carafate
Oral suspension and tablets; Human product
Contraindications · when not to use
- Hypersensitivity to sucralfate or excipients.
Precautions & monitoring
- Renal failure increases aluminum toxicity risk. Suspension: oral route only and monitor diabetic glycemia. Tablets: aspiration concern with impaired swallowing.
Human labeling; this does not establish veterinary approval or animal-specific eligibility.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Human-label concerns include constipation, hypersensitivity, bezoars and aluminum accumulation with impaired renal function; animal frequencies are not established.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
A veterinary dose is not verified; do not apply human instructions to animals. Suspension/tablet equivalence is not demonstrated by the suspension label.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Carafate
Oral suspension and tablets; Human product
- Can reduce absorption of fluoroquinolones, tetracycline, thyroid hormone, digoxin and other drugs; prescriber must plan separation and monitoring. Aluminum products increase aluminum exposure.
Monitoring
Assess renal function, gastrointestinal response, constipation, swallowing risk and concurrent drugs.
Client counseling
Ask the prescriber to schedule separation from interacting medicines such as fluoroquinolones, thyroid hormone and tetracyclines. Suspension is oral only.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Use the dispensed product's storage instructions; shake commercial suspension as directed and verify concentration.
Brands, formulations & ingredient identity
Active ingredients
Sucralfate
Carafate is a brand synonym for sucralfate.
Tablets and commercial oral suspension identify the same active ingredient but are different presentations. Check concentration and whether a liquid is commercial or compounded.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Carafate
- Formulation
- Oral suspension and tablets
- Label / product scope
- Human product
Check the prescribed presentation; human labeling does not establish animal dosing.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →